 |
 |
 |
|
 | |||||
| |||||||||
 | |||||||||
|
|
 |
|
|
FDA Drug Safety Podcasts
Transcript Welcome to the Food and Drug Administration's drug safety update. I am Mandy Eisemann from F-D-A's Center for Drug Evaluation and Research. On November 8, 2007, we issued a public health advisory about revisions to the product labeling for the erythropoiesis- [eh RITH ro POH eh sis] stimulating agents, known as E-S-As. The advisory alerts patients and health-care providers that we have approved revised labeling for the ESAs. The revisions clarify how to safely and effectively use these products and strengthen the information about risks from using E-S-As. The advisory applies patients taking E-S-As who have cancer or chronic kidney failure or who are taking zidovudine [zye DOE vue deen] for H-I-V. To hear the full public health advisory, listen to part two of this Podcast. We are asking health care professionals and patients to report serious side effects after using E-S-As to us through the MedWatch program by phone at 1-800-F-D-A-ten-88 or by the Internet at F-D-A dot G O V slash M-E-D-W-A-T-C-H. Additional Information
Date created: November 8, 2007 |
|
|
||||||
 | ||||||
|
||||||